DelveInsight's Ovarian Cancer Pipeline Report Highlights 180+ Industry Trailblazers | Allarity Therapeutics, OSE Immunotherapeutics, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals

The Ovarian Cancer treatment landscape is evolving, driven by cutting-edge research and innovative therapies from top pharmaceutical players, offering renewed hope for patients.

DelveInsight's "Ovarian Cancer Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Ovarian Cancer market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging Ovarian Cancer drugs, the Ovarian Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Ovarian Cancer Pipeline Report
• DelveInsight's Ovarian Cancer Pipeline analysis depicts a robust space with 180+ active players working to develop 200+ pipeline drugs for Ovarian Cancer treatment.
• The leading Ovarian Cancer companies include Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-La Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, GlaxoSmithKline (GSK), AbbVie, Eli Lilly, Novartis, Roche, Verastem Oncology, Corcept Therapeutics, AstraZeneca, Genmab, Genelux Corporation, Mural Oncology, Daiichi Sankyo, Merck, Sutro Biopharma, Bristol-Myers Squibb, and others are evaluating their lead assets to improve the Ovarian Cancer treatment landscape.
• Key Ovarian Cancer pipeline therapies in various stages of development include Avutometinib (VS-6766) + Defactinib (VS-6063), Relacorilant (CORT125134), IMFINZI (durvalumab), Rinatabart sesutecan (Rina-S), Olvimulogene nanivacirepvec (Olvi-Vec), Nemvaleukin alfa (ALKS 4230), Catequentinib (anlotinib/AL3818), Raludotatug deruxtecan (R-DXD/DS-6000A), Luveltamab tazevibulin (STRO-002), Sacituzumab tirumotecan, Atezolizumab, Tisotumab Vedotin, SON-1010, and others.
• In March 2025, IMUNON, Inc. announced that the FDA is aligned with the protocol for its Phase 3 pivotal trial, OVATION 3, of its lead candidate IMNN-001 for treating women with newly diagnosed advanced ovarian cancer. The company is initiating trial sites and preparing to enroll participants.
• In February 2025, Gradalis, Inc. announced that the FDA granted RMAT designation for its personalized immunotherapy, Vigil® (Gemogenovatucel-T), based on positive results from the Phase 2b VITAL trial. Vigil is being developed as a maintenance treatment for women with advanced Stage IIIb/IV ovarian cancer who are HRP, have high clonal tumor mutation burden, and are in complete response after surgery and chemotherapy.
• In February 2025, the FDA granted fast-track designation to CUSP06, a CDH6-directed antibody-drug conjugate (ADC), for the treatment of patients with platinum-resistant ovarian cancer.
• In January 2025, the FDA accepted and prioritized the review of the new drug application (NDA) for the combination of avutometinib (VS-6766) and defactinib (VS-6063) to treat adult patients with KRAS-mutant recurrent low-grade serous ovarian cancer who have had at least one prior systemic therapy.
• In December 2024, Verastem Oncology announced the FDA's acceptance of its New Drug Application (NDA) for avutometinib, a RAF/MEK clamp, combined with defactinib, a FAK inhibitor, under the accelerated approval pathway for treating KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) in adults after prior systemic therapy.

Request a sample and discover the recent breakthroughs happening in the Ovarian Cancer pipeline landscape @ https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Ovarian Cancer Overview
Ovarian cancer is the deadliest gynecological cancer and the fifth leading cause of cancer-related deaths in women. Most cases are diagnosed at an advanced stage, leading to poor outcomes. Current screening methods, including CA-125 assays and transvaginal ultrasounds, have shown limited effectiveness in reducing mortality.

Epithelial ovarian cancer has four main histological types: serous, endometrioid, clear cell, and mucinous, with rarer subtypes like Brenner and seromucinous tumors. It is further classified into Type I (low-grade, slow-growing, better prognosis) and Type II (high-grade, aggressive, poor prognosis) tumors. Type II tumors, often linked to p53 mutations, are more advanced at diagnosis and highly proliferative.

Standard treatment includes surgery and platinum-based chemotherapy, with anti-angiogenic bevacizumab and PARP inhibitors gaining traction. However, high recurrence rates and treatment resistance highlight the urgent need for improved early detection and novel targeted therapies.

Find out more about Ovarian Cancer medication @ https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Ovarian Cancer Treatment Analysis: Drug Profile
Atezolizumab: Genentech
Atezolizumab is a humanized kappa IgG1 monoclonal antibody produced in Chinese hamster 0vary cells. Engineered to eliminate Fc-effector function, it features a single amino acid substitution (asparagine to alanine) at position 298, preventing Fc receptor binding and PD-L1+ cell depletion. By targeting PD-L1, it blocks interactions with PD-1 and B7.1, restoring T-cell activity. Currently, Atezolizumab is in Phase 3 clinical trials for ovarian cancer treatment.

Tisotumab Vedotin: Genmab
Tisotumab vedotin (HuMax-TF, HuMax®-TF-ADC, or TF-011-MMAE) is an antibody-drug conjugate (ADC) targeting tissue factor (TF), a protein involved in tumor signaling and angiogenesis. It consists of an anti-TF antibody linked to monomethyl auristatin E (MMAE) via a cleavable mc-val-cit-PABC linker. The drug is in Phase 2 clinical trials for ovarian cancer.

SON-1010: Sonnet Biotherapeutics
SON-1010 is a modified version of human IL-12 developed using Sonnet's fully human albumin-binding (FHAB®) platform, designed to enhance tumor microenvironment targeting and extend pharmacokinetics and pharmacodynamics. Sonnet and Roche have partnered to evaluate SON-1010 in combination with atezolizumab for platinum-resistant ovarian cancer (PROC). The drug is currently in Phase I/II development for ovarian cancer.

Key Ovarian Cancer Therapies and Companies
• Avutometinib (VS-6766) + Defactinib (VS-6063): Verastem Oncology
• Relacorilant (CORT125134): Corcept Therapeutics
• IMFINZI (durvalumab): AstraZeneca
• Rinatabart sesutecan (Rina-S): ProfoundBio/Genmab
• Olvimulogene nanivacirepvec (Olvi-Vec): Genelux Corporation
• Nemvaleukin alfa (ALKS 4230): Mural Oncology
• Catequentinib (anlotinib/AL3818): Advenchen Laboratories
• Raludotatug deruxtecan (R-DXD/DS-6000A): Daiichi Sankyo and Merck
• Luveltamab tazevibulin (STRO-002): Sutro Biopharma
• Sacituzumab tirumotecan: Merck and Kelun-Biotech

Learn more about the novel and emerging Ovarian Cancer pipeline therapies @ https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Ovarian Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Ovarian Cancer Pipeline Report
• Coverage: Global
• Key Ovarian Cancer Companies: Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-La Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, GlaxoSmithKline (GSK), AbbVie, Eli Lilly, Novartis, Roche, Verastem Oncology, Corcept Therapeutics, AstraZeneca, Genmab, Genelux Corporation, Mural Oncology, Daiichi Sankyo, Merck, Sutro Biopharma, Bristol-Myers Squibb, and others.
• Key Ovarian Cancer Pipeline Therapies: Avutometinib (VS-6766) + Defactinib (VS-6063), Relacorilant (CORT125134), IMFINZI (durvalumab), Rinatabart sesutecan (Rina-S), Olvimulogene nanivacirepvec (Olvi-Vec), Nemvaleukin alfa (ALKS 4230), Catequentinib (anlotinib/AL3818), Raludotatug deruxtecan (R-DXD/DS-6000A), Luveltamab tazevibulin (STRO-002), Sacituzumab tirumotecan, Atezolizumab, Tisotumab Vedotin, SON-1010, and others.

Dive deep into rich insights for drugs used for Ovarian Cancer treatment; visit @ https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Ovarian Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Ovarian Cancer Pipeline Therapeutics
6. Ovarian Cancer Pipeline: Late-Stage Products (Phase III)
7. Ovarian Cancer Pipeline: Late-Stage Products (Phase III)
8. Ovarian Cancer Pipeline: Mid-Stage Products (Phase II)
9. Ovarian Cancer Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.